Long-term Safety and Efficacy Follow-up of BIIB111 for the Treatment of Choroideremia and BIIB112 for the Treatment of X-Linked Retinitis Pigmentosa

NCT03584165 · clinicaltrials.gov ↗

PHASE3

Phase

ENROLLING_BY_INVITATION

Status

330

Enrollment

OTHER

Sponsor class

Conditions

Choroideremia
X-Linked Retinitis Pigmentosa

Interventions

GENETIC: BIIB111
GENETIC: BIIB112

Sponsor

NightstaRx Ltd, a Biogen Company